Overview

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

Status:
Completed
Trial end date:
2020-01-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy and safety of ixekizumab to guselkumab in participants with moderate-to-severe plaque psoriasis.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Ixekizumab